Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUTL
Previous Symbol
CUSIPN/A
Phone44-20-3829-6230
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees126
Outstanding Shares38,790,000
Market Cap$1.36 billion
OptionableNot Optionable
Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions
What is Autolus Therapeutics' stock symbol?
Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."
What price target have analysts set for AUTL?
5 Wall Street analysts have issued 12 month price targets for Autolus Therapeutics' shares. Their forecasts range from $37.00 to $45.00. On average, they expect Autolus Therapeutics' share price to reach $40.00 in the next year. This suggests that the stock has a possible downside of 2.9%. View Analyst Price Targets for Autolus Therapeutics.
What is the consensus analysts' recommendation for Autolus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Autolus Therapeutics.
Has Autolus Therapeutics been receiving favorable news coverage?
Media stories about AUTL stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Autolus Therapeutics earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Autolus Therapeutics' key competitors?
Some companies that are related to Autolus Therapeutics include Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX) and Spark Therapeutics (ONCE).
Who are Autolus Therapeutics' key executives?
Autolus Therapeutics' management team includes the folowing people:
- Dr. Christian Martin Itin, Chairman & CEO (Age 54)
- Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 46)
- Mr. Andrew J. Oakley, CFO & Sr. VP (Age 56)
- Mr. Christopher Vann, Sr. VP & COO (Age 53)
- Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 53)
When did Autolus Therapeutics IPO?
(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.
When does the company's lock-up period expire?
Autolus Therapeutics' lock-up period expires on Wednesday, December 19th. Autolus Therapeutics had issued 8,823,530 shares in its initial public offering on June 22nd. The total size of the offering was $150,000,010 based on an initial share price of $17.00. After the end of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Who are Autolus Therapeutics' major shareholders?
Autolus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Capital World Investors (1.58%), Artal Group S.A. (1.29%), Capital International Investors (1.26%), Sphera Funds Management LTD. (0.76%), Partner Fund Management L.P. (0.57%) and FIL Ltd (0.40%).
Which major investors are selling Autolus Therapeutics stock?
AUTL stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, FIL Ltd, Laurion Capital Management LP, Victory Capital Management Inc., Artal Group S.A. and Pentwater Capital Management LP.
Which major investors are buying Autolus Therapeutics stock?
AUTL stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Sphera Funds Management LTD., Allianz Asset Management GmbH, Essex Investment Management Co. LLC, Blair William & Co. IL and Partner Fund Management L.P..
How do I buy shares of Autolus Therapeutics?
Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Autolus Therapeutics' stock price today?
One share of AUTL stock can currently be purchased for approximately $41.20.
How big of a company is Autolus Therapeutics?
Autolus Therapeutics has a market capitalization of $1.36 billion. Autolus Therapeutics employs 126 workers across the globe.
What is Autolus Therapeutics' official website?
How can I contact Autolus Therapeutics?
Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]
MarketBeat Community Rating for Autolus Therapeutics (NASDAQ AUTL)
MarketBeat's community ratings are surveys of what our community members think about Autolus Therapeutics and other stocks. Vote "Outperform" if you believe AUTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
